ArticleInternational journal of clinical and experimental medicine2015
Analysis of plasma MicroRNAs to identifying early diagnostic molecule for gastric cancer.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives.World journal of gastroenterology · 2018Pooled it
- Exosomal circ_0001190 Regulates the Progression of Gastric Cancer via miR-586/SOSTDC1 Axis.Biochemical genetics · 2022Article
- The role of miR-200 family in the regulation of hallmarks of cancer.Frontiers in oncology · 2022Review
- Circular RNA hsa-circ-0007766 modulates the progression of Gastric Carcinoma via miR-1233-3p/International journal of medical sciences · 2020Article
- Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma.Cancer biomarkers : section A of Disease markers · 2018Article
- A GDF15 3' UTR variant, rs1054564, results in allele-specific translational repression of GDF15 by hsa-miR-1233-3p.PloS one · 2017Article
- Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains the second leading cause of cancer-related death worldwide. Owing to the lack of early diagnostic techniques, GC is often diagnosed at advanced stage and that leading to low survival rate. Growing evidences have been suggesting that circulating microRNAs play an important role in earlier diagnostic of disease. In the present study, we analyze the circulating miRNAs expression in plasma of volunteers with/without GC aiming to identifying early diagnostic biomarkers. Plasma samples were collected form 6 volunteers including 3 early patients with GC and 3 healthy adults. And then miRNAs microarrays were performed to detect the expression profile of miRNAs in these plasma samples. For further validate the results from miRNAs microarray, qRT-PCR was performed. Finally, target genes of miRNAs were predicted by bioinformatic means. Compared to control plasma, 11 up-regulated and 13 down-regulated miRNAs were detected in the plasma from earlier patients with GC (fold change ≥ 2, P < 0.05). Then, 5 differential expression miRNAs (miR-223, miR-19b-2*, miR-194*, miR-141, miR-1233) were chose to confirm by qRT-PCR. The result is nearly consistent with previous data from miRNAs microarray. Finally, 53 target genes of the 5 miRNAs are predicted by bioinformatics. These differential expression miRNAs may be used as biomarker candidates for minimally invasive diagnosis of early patients with GC in the future.
Indexed as
Identifiers
26064265PMC4443099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.